

**NOVEMBER 2010 PBAC MEETING OUTCOMES - Deferrals**

<b>DRUG AND FORM</b>	<b>DRUG USE AND TYPE</b>	<b>LISTING REQUESTED BY SPONSOR</b>	<b>PBAC OUTCOME AND COMMENTS</b>
Adrenaline, injections, 150 mcg in 0.3 mL and 300 mcg 0.3 mL, single dose syringe auto-injector, EpiPen Jr <sup>®</sup> and EpiPen <sup>®</sup>  Alphapharm Pty Ltd  Minor submission	Severe allergic reactions	A change from an Authority Required listing to an Authority Required (Streamlined) listing was requested.	The PBAC deferred making a recommendation to seek comment on the proposed change from the Australasian Society of Clinical Immunology and Allergy (ASCIA).
		Sponsor's comments:	Alphapharm supports the decision to seek comment from the ASCIA.
Meloxicam, tablet, 7.5 mg and 15 mg, Moxicam <sup>®</sup>  Alphapharm Pty Ltd  Minor submission	Anti-inflammatory	The addition of a NOTE that states that meloxicam tablets and capsules are bioequivalent was requested.	The PBAC deferred making a recommendation on the wording of the NOTE that would allow substitution to occur to seek further advice from the Department regarding the appropriate wording of such a NOTE.
		Sponsor's comments:	Alphapharm welcomes the inclusion of a note to indicate that the capsule and tablet formulations may be substituted.